OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Dragged off to the shops today but checked the standard websites/papers on my return -certainly no indication of anything on OXB, rumour or fact. Perhaps tomorrow? Still, at least one of my other holdings, SKP, got a mention in the FT today so can't complain.

Have seen nothing in the Sunday papers regarding OXB - they are very good at stopping any leaks it seems.

Citywire.co.uk
Published: 07:00 Sunday 30 January 2005 < PREV | 1 | 2 | NEXT > TOTAL PAGES: 2
By: Graeme Davies, Investment Correspondent Back To Latest News Printable Version

Related Articles
Shrewd Snapshot: Jordan builds in Oxford:
07:00 Wed 26 January 2005 read
Shrewd Snapshot: Oxford Biomedica bags more Russian interest:
07:00 Sun 23 January 2005 read

Russian entrepreneur Boris Jordan has added to his holding at Oxford Biomedica and Swedish activist Peter Gyllenhammar has added to his stake at European Colour.

* Jordan's Sputnik vehicle snapped up another 166,666 shares on Thursday at 26.75p each to take its total holding in the 101 million gene-based therapeutics business (OXB) to 4.15 million shares or 1.2%.

The American-born Russian banking entrepreneur's vehicle is acting in concert with Garboldi Investment and Sulidad Invest & Trade and the three vehicles own more than 3% of Oxford between them.

Oxford's shares shot up earlier this month when it announced it was in merger talks with an unnamed third party however after a rise from 16.75p to 27p this month it gave up 1.25p on Friday to close at 25.75p.

Jordan made his fortune advising on Russia's privatisations and also set up its first Western-style investment bank. Oxford's shares drifted in the second half of last year as progress stalled on its licensing deals.

What a brilliant couple of goals by Rooney yesterday it has definetely made by
weekend. Go on u reds!

Yesterday I bought the FT, The Times and The Sun (for sports pages) and today
The Sunday Times I did not find any articles regarding OXB. I have not managed
to find any recent news when I've flicked through the Bloomberg Business TV
Channel neither.

I'm sure this week will see the share price regain its upwards movement
towards 30p or drop close to 21p.

After this post I'm not going anywhere near a computer for a week (will remind
me too much of work tee hee hee hee!while I'm off)however, I will find time to
follow events through watching Bloomberg.

Will the share price continue its upwards momentum? Will the price continue
its fall in the previous session? Tommorrow's session and the remainder of the
week will be interesting.

Look foward to reading all the comments on the board in a week's time.

Good Luck All!

This is very good news...


Oxford Biomedica signs Lentivector technology licensing agreement
AFX


LONDON (AFX) - Oxford BioMedica PLC said it has signed a further licence agreement for its LentiVector technology with a large unnamed biopharmaceutical company.

Under terms of the agreement, Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee, however further financial details were not disclosed.

The agreement permits the use of the company's proprietary LentiVector gene delivery system -- a powerful technology for the delivery of genes to a wide range of cell and tissue types -- for research activities.

'The versatility and safety of lentiviral vectors make them the system of choice for gene target validation in the drug discovery process as well as for the direct therapeutic applications in neurotherapy that Oxford BioMedica is pursuing,' Senior Vice President Commercial Development, Peter Nolan commented.

'We are pleased that an increasing number of companies are using the LentiVector technology and we expect to establish a number of new partnerships around the technology in the near future.'

etain.lavelle@afxnews.com

This is a strange company or at least the share dealings seem odd to me. I has a series of good news, but every time one would expect the price to go up it heads south.

I have read in a journal at the weekend that the opinion was that it looked good but suggested locking into profits if any.

I am well into profit and intend holding for the while but would like to know what am I missing.

Just checking in for a quick afternoon peek at the prices etc. Totally agree with you Fred - I suppose an rns which simply shows "more of the same" is initially viewed as neutral by prospective shareholders, whereas a totally new agreement is positive because it demonstrates that OXB technology has more wide-ranging applications? Other than that, I cannot understand the small reduction in the price. Perhaps it will shoot up tomorrow?

And your point Queen?

Looking at the 1 year chart - it is possible that we could soon see a rise to the mid-30s - if we are currently in the 2nd wave. Any TA experts out there to advise?

Thought better of it pachandl. Dull day again.

Shrewd Snapshot: Sputnik still orbiting Oxford
Published: 07:00 Thursday 03 February 2005 < PREV | 1 | 2 | 3 | 4 | NEXT >

Private investor Boris Jordan has bought yet more of Oxford Biomedica amid a string of shrewd deals at companies as diverse as PFI Infrastructure, Blavod Extreme Spirits and NewMedia Spark.

* American-born Russian banker Jordan has been steadily building a stake in 90 million Oxford Biomedica for the past few weeks through his Sputnik Group which is acting in concert with Garboldi Investment and Sulidad Invest & Trade.

His latest purchase of 200,000 shares at 23.62p each takes the Sputnik concert party's total stake in Oxford (OXB) to 12.775 million or 3.45%. His first purchase came at 17.5p in mid-January but since then it has surged as high as 27.5p after the company confirmed it was in merger talks.

It closed last night at 24.25p.

Sputnik is not the only notable investor to have bought shares in Oxford in recent days with Credit Agricole and UBS both building up significant stakes in recent days on behalf of clients through contracts for difference. Credit Agricole holds 7.34% and UBS 3.2%.

All quiet on the Western Front - nothing reported in the weekend press. OXB and ? are clearly talking in a leak-proof environment.

Don't worry, Pachandl as OXB will merge with a highflyer soon. It is cheap now at 23p.

Not yet Hlye:

Oxford Biomedica PLC
07 February 2005



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')


Termination of discussions


On 19 January 2005 the Board of Oxford BioMedica announced that it had received
an approach from a third party regarding a potential merger, which may or may
not lead to an offer for the Company.


The Board of Oxford BioMedica announces that the discussions that followed this
unsolicited approach have terminated.


7 February 2005


Enquiries:


Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer

Rothschild Tel: +44 (0) 20 7280 5000
Dr. Lynn Drummond


N M Rothschild & Sons Limited ('Rothschild'), which is authorised and regulated
by the Financial Services Authority in the United Kingdom, acts for Oxford
BioMedica plc and no one else in relation to the contents of this announcement
and will not be responsible to anyone other than Oxford BioMedica plc for
providing the protections afforded to clients of Rothschild nor for providing
advice in relation to the contents of this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange

see this one free fall for a week or so. Some very good news is now required to get this one back on track.

It had better be good...this was NOT the way to treat their shareholders....very autocratic.So,do we all pile back in at 14.50???Can someone inform me as to how much of their research is based on animal experiments.Thanks.

Shame, but two things which are interesting and promising from recent events:- that OXB is prepared to talks about merges or take overs and possibly they think they are worth more than 27p a share. Although still in profit on my holding I think I will hold for future results Annual report 2/3/05 Prelims results 3/3/05.

Don't know what proportion of animal testing is used, but await testing on the human species with interest!

Check out their website, I think their experiments have been on terminally-ill patients most recently and usual arrangements (on humans) before that. The later tests are unusual in that the patients must be certified they have a limited life (presumably because they need an autopsy) so it is not easy to determine the before/after (effectiveness) for the treatment, but I understood their tests of about 2-years ago were above expectations.
Bid/Merger
I suspect it is not OXB that is willing to consider a deal; rather that it is a Listing requirement that talks proceede. AK may be mistreating his (retail) shareholders as suggested above, but I suspect he'd rather be doing a deal or setting-up another trial, than talking to suits.
Resaults/Update
There may be some good news with the results so I'm in two minds about selling out; as often happens the sp rises in the weeks before the news -and these days news seems to be somewhat leaky for all stocks in general.
I hold OXB at an average about this level and wonder if trying to trade my position isn't risk-taking - as I don't think the price will slip to silly levels (eg 12p); what say you?

Afternoon All!

Enjoyed a lovely break from work last week especially the Super Reds victory
at Highbury (snigger! snigger! tee hee hee tee).

Getting back to today not I'm not surprised to see that the bid/merger talks
have been terminated and the sp has tumbled down past my forecast last week of
21p. Glad I sold up over a week ago and have not been tempted to rush back in
as yet.Hopefully I can dive back in and catch the next rise or maybe not.